Patient characteristics
| Last visit before first shot | 15 days after the second shot | |||
| Av.Obs. | Av.Obs | |||
| Age, mean (SD) | 40 | 52.85 (10.41) | ||
| Female, n (%) | 40 | 22 (55) | ||
| Disease duration, years, mean (SD) | 40 | 11 (9.01) | ||
| Axial, n (%) | 40 | 6 (15) | ||
| Psoriasis, n (%) | 40 | 33 (82.5) | ||
| Polyarticular, n (%) | 40 | 18 (45) | ||
| PsAID12, mean (SD) | 40 | 3.94 (2.4) | ||
| MMAS-4, median (min–max) | 38 | 0 (0–1) | ||
| DAPsA at vaccine, mean (SD) | 40 | 11.34 (7.81) | ||
| PASI, mean (SD) | 40 | 0.56 (1.01) | ||
| CDAI, mean (SD) | 40 | 7.06 (5.23) | 40 | 7.10* (5.27) |
| CDAI remission/LDA, n (%) | 40 | 28 (73) | 40 | 23† (67.5) |
| Glucocorticoid, n (%) | 40 | 11 (27.5) | ||
| Glucocorticoid dose, mean (SD) | 11 | 4.66 (1.97) | ||
| Combotherapy, n (%) | 40 | 19 (42.5) | ||
| Methotrexate, n (%) | 40 | 12 (40) | ||
| Sulfasalazine, n (%) | 40 | 7 (17.5) | ||
| bDMARD treatment first line, n (%) | 40 | 7 (17.5) | ||
| bDMARD treatment second line, n (%) | 40 | 30 (75) | ||
| bDMARD treatment third line, n (%) | 40 | 3 (7.5) | ||
| Adalimumab, n (%) | 40 | 13 (32.5) | ||
| Infliximab, n (%) | 40 | 11 (27.5) | ||
| Certolizumab, n (%) | 40 | 7 (17.5) | ||
| Etanercept, n (%) | 40 | 7 (17.5) | ||
| Golimumab, n (%) | 40 | 2 (5) | ||
*Paired t-test, p=0.92.
†McNemar’s test, p=0.31.
Av.Obs., available observations; bDMARD, biologic disease-modifying antirheumatic drugs; CDAI, Clinical Disease Activity Index; DAPsA, Disease Activity in Psoriatic Arthritis; LDA, low disease activity; MMAS-4, Morisky Medication Adherence Score on 4 Items; PASI, Psoriasis Area Severity Index; PsAID12, Psoriatic Arthritis Impact of Disease.